

Angola

Support for Vaccine: Inactivated Polio Virus This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Republic of Angola						
2. Vaccine grant number:	15-AGO-08h-Y, 1518-AGO-25c-X, 19-AGO-25c-X, 20-AGO-25c-X						
3. Date of Decision Letter:	30/09/2019						
4. Date of the Partnership Framework Agreement:	04/10/2013						
5. Programme title:	New Vaccine Support (NVS), Inactivated Polio Virus, Routine						
6. Vaccine type:	Inactivated Polio Virus						
7. Requested product presentation and formulation of vaccine:	Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID						
8. Programme Duration:¹	2015-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2015-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	3,094,076	2,551,000	-	-	-	-	5,645,076
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2015	15-AGO-08h-Y	785,500				
	Disbursement						
	Disbursement date		Amount (US\$)				
	07 July, 2015		785,500				
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2015-2019	2020	2021				
Number of vaccine doses		1,149,000	-				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Annual Amounts (US\$)	3,094,076	2,551,000	-						
13. Procurement agency:	UNICEF								
14. Self-procurement:	Not applicable								
15. Co-financing obligations:	<p style="text-align: center;">Not applicable</p> <p>Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.</p>								
16. Operational support for campaigns:	<p style="text-align: center;">Not applicable</p>								
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels for all vaccines including buffer stock, by end number of children to be vaccinated for all vaccines, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> <p>31 March 2020</p> <p>15 May 2020</p> </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels for all vaccines including buffer stock, by end number of children to be vaccinated for all vaccines, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2020</p> <p>15 May 2020</p>	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates								
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels for all vaccines including buffer stock, by end number of children to be vaccinated for all vaccines, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2020</p> <p>15 May 2020</p>								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat								
18. Financial clarifications:	<p>Country shall provide the following clarifications to Gavi*:</p> <p>Not applicable</p> <p>* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</p>								
19. Other conditions:	<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>								

Insurance: According to Gavi grant management requirements, the Ministry of Health will be responsible for all program assets (including vaccines and related supplies, cold chain equipment and other tangible assets (to be procured through UN agencies) at both central and regional levels depending on the size of the program. Availability of the budget: If possible and at reasonable cost, the Ministry of Health will have to take out all-risk insurance and general liability insurance with reputable and strong insurance companies by choosing a cover corresponding to the policies held by similar organizations that carry out comparable activities, otherwise the Ministry of Health will have to provide a budget line to supply the replacement of damaged or missing vaccines or assets.

Signed by,

Signed by,

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes

30/09/2019